# MAGED2

## Overview
MAGED2 is a gene that encodes the protein MAGE family member D2, which is part of the melanoma-associated antigen (MAGE) family. This protein is primarily involved in cellular signaling and stress response pathways, particularly under hypoxic conditions. As a regulatory protein, MAGE-D2 plays a crucial role in the cAMP/PKA signaling pathway, which is essential for maintaining renal salt reabsorption and proper kidney function. It interacts with various proteins, including Gαs and p53, influencing processes such as autophagy, water balance, and cellular stress responses. Mutations in the MAGED2 gene are linked to transient antenatal Bartter syndrome and X-linked nephrogenic diabetes insipidus, highlighting its clinical significance in renal pathophysiology (McLeod2007MAGED2:; Nasrah2023MAGED2; Seaayfan2022MAGED2).

## Function
The MAGED2 gene encodes a protein that plays a critical role in cellular signaling and stress response pathways, particularly under hypoxic conditions. In healthy human cells, MAGED2 is involved in the regulation of the cAMP/PKA signaling pathway, which is essential for maintaining renal salt reabsorption and proper kidney function. MAGED2 interacts with the Gαs protein, preventing its internalization and ensuring continuous cAMP production and PKA activation, which are crucial for renal salt transport (Nasrah2023MAGED2; Seaayfan2022MAGED2).

MAGED2 also modulates the expression of aquaporin-2 (AQP2) in kidney collecting duct cells, which is vital for water reabsorption. This regulation is mediated through vasopressin-induced signaling pathways, highlighting MAGED2's role in maintaining water balance and kidney function (Reusch2022MAGED2).

Additionally, MAGED2 is implicated in the regulation of autophagy under stress conditions. It inhibits autophagy by modulating the cAMP/PKA pathway, preventing excessive autophagic activity in healthy cells. This function is particularly important under hypoxic and oxidative stress, where MAGED2 depletion leads to increased autophagy markers (Nasrah2023MAGED2).

## Clinical Significance
Mutations in the MAGED2 gene are associated with transient antenatal Bartter syndrome, a condition characterized by severe renal salt wasting, polyhydramnios, and preterm labor. This syndrome is particularly severe during fetal development but resolves spontaneously after birth as renal function normalizes (VargasPoussou2021Pathophysiological; Seaayfan2022MAGED2). The mutations in MAGED2 are often nonsense, frameshift, or splice site variants, leading to truncated proteins or unstable mRNAs (Legrand2017Prevalence). These genetic alterations disrupt the normal function of MAGED2, which is crucial for the regulation of sodium transporters like NKCC2 and NCC, leading to the symptoms observed in Bartter syndrome (ValiñoRivas2018MAGE).

MAGED2 mutations are also linked to X-linked nephrogenic diabetes insipidus, a condition where the kidneys cannot concentrate urine properly (Yan2024Identification). Altered expression of MAGED2 during kidney injury, such as acute kidney injury (AKI) and chronic kidney disease (CKD), suggests its role in the stress response and regulation of sodium transport, potentially contributing to volume overload and hypertension (ValiñoRivas2018MAGE). The gene's expression is upregulated in response to stressors, indicating a protective mechanism against cell injury (ValiñoRivas2018MAGE).

## Interactions
MAGED2 interacts with several proteins, influencing various cellular processes. It is known to interact with the p53 protein, impairing p53's transcriptional activity in human cancer cells when both proteins are co-localized in the same subcellular compartment. This interaction is labile and may depend on the cellular microenvironment (McLeod2007MAGED2:). MAGED2 also interacts with the Gαs protein, playing a crucial role in GPCR signaling under hypoxic conditions. It prevents the MDM2-mediated internalization of Gαs, thereby maintaining cAMP levels and PKA activity, which are essential for cellular signaling (Seaayfan2022MAGED2).

In the context of kidney injury, MAGED2 is upregulated and may interact with sodium transporters NCC and NKCC2, potentially enhancing their activity and contributing to sodium reabsorption (ValiñoRivas2018MAGE). Additionally, MAGED2 is involved in the regulation of HIF-1α expression under hypoxic conditions, where it is necessary for the maximal induction of HIF-1α through the cAMP/PKA signaling pathway (Seaayfan2022Reciprocal). These interactions highlight MAGED2's role in modulating key signaling pathways and cellular responses.


## References


[1. (Nasrah2023MAGED2) Sadiq Nasrah, Aline Radi, Johanna K. Daberkow, Helmut Hummler, Stefanie Weber, Elie Seaayfan, and Martin Kömhoff. Maged2 depletion promotes stress-induced autophagy by impairing the camp/pka pathway. International Journal of Molecular Sciences, 24(17):13433, August 2023. URL: http://dx.doi.org/10.3390/ijms241713433, doi:10.3390/ijms241713433. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms241713433)

[2. (Reusch2022MAGED2) Björn Reusch, Malte P. Bartram, Claudia Dafinger, Nicolàs Palacio-Escat, Andrea Wenzel, Robert A. Fenton, Julio Saez-Rodriguez, Bernhard Schermer, Thomas Benzing, Janine Altmüller, Bodo B. Beck, and Markus M. Rinschen. Maged2 controls vasopressin-induced aquaporin-2 expression in collecting duct cells. Journal of Proteomics, 252:104424, February 2022. URL: http://dx.doi.org/10.1016/j.jprot.2021.104424, doi:10.1016/j.jprot.2021.104424. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jprot.2021.104424)

[3. (ValiñoRivas2018MAGE) Lara Valiño-Rivas, Leticia Cuarental, Mateo Agustin, Holger Husi, Pablo Cannata-Ortiz, Ana B Sanz, Harald Mischak, Alberto Ortiz, and Maria Dolores Sanchez-Niño. Mage genes in the kidney: identification of maged2 as upregulated during kidney injury and in stressed tubular cells. Nephrology Dialysis Transplantation, 34(9):1498–1507, December 2018. URL: http://dx.doi.org/10.1093/ndt/gfy367, doi:10.1093/ndt/gfy367. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/ndt/gfy367)

[4. (Legrand2017Prevalence) Anne Legrand, Cyrielle Treard, Isabelle Roncelin, Sophie Dreux, Aurélia Bertholet-Thomas, Françoise Broux, Daniele Bruno, Stéphane Decramer, Georges Deschenes, Djamal Djeddi, Vincent Guigonis, Nadine Jay, Tackwa Khalifeh, Brigitte Llanas, Denis Morin, Gilles Morin, François Nobili, Christine Pietrement, Amélie Ryckewaert, Rémi Salomon, Isabelle Vrillon, Anne Blanchard, and Rosa Vargas-Poussou. Prevalence of novel maged2 mutations in antenatal bartter syndrome. Clinical Journal of the American Society of Nephrology, 13(2):242–250, November 2017. URL: http://dx.doi.org/10.2215/cjn.05670517, doi:10.2215/cjn.05670517. This article has 42 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.2215/cjn.05670517)

[5. (Seaayfan2022MAGED2) Elie Seaayfan, Sadiq Nasrah, Lea Quell, Maja Kleim, Stefanie Weber, Hemmo Meyer, Kamel Laghmani, and Martin Kömhoff. Maged2 is required under hypoxia for camp signaling by inhibiting mdm2-dependent endocytosis of g-alpha-s. Cells, 11(16):2546, August 2022. URL: http://dx.doi.org/10.3390/cells11162546, doi:10.3390/cells11162546. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells11162546)

[6. (Seaayfan2022Reciprocal) Elie Seaayfan, Sadiq Nasrah, Lea Quell, Aline Radi, Maja Kleim, Ralph T. Schermuly, Stefanie Weber, Kamel Laghmani, and Martin Kömhoff. Reciprocal regulation of maged2 and hif-1α augments their expression under hypoxia: role of camp and pka type ii. Cells, 11(21):3424, October 2022. URL: http://dx.doi.org/10.3390/cells11213424, doi:10.3390/cells11213424. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells11213424)

[7. (VargasPoussou2021Pathophysiological) Rosa Vargas-Poussou. Pathophysiological aspects of the thick ascending limb and novel genetic defects: helix syndrome and transient antenatal bartter syndrome. Pediatric Nephrology, 37(2):239–252, March 2021. URL: http://dx.doi.org/10.1007/s00467-021-05019-6, doi:10.1007/s00467-021-05019-6. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00467-021-05019-6)

[8. (Yan2024Identification) Xu Yan, Yueyue Hu, Xin Zhang, Xia Gao, Yang Zhao, Haiying Peng, Liu Ouyang, and Changjun Zhang. Identification of a novel intronic mutation of maged2 gene in a chinese family with antenatal bartter syndrome. BMC Medical Genomics, January 2024. URL: http://dx.doi.org/10.1186/s12920-024-01797-8, doi:10.1186/s12920-024-01797-8. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12920-024-01797-8)

[9. (McLeod2007MAGED2:) Howard McLeod, Robert Culverhouse, Wanghai Zhang, Jue Zeng, Rainer Brachmann, and Chris Papageorgio. Maged2: a novel p53-dissociator. International Journal of Oncology, November 2007. URL: http://dx.doi.org/10.3892/ijo.31.5.1205, doi:10.3892/ijo.31.5.1205. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.31.5.1205)